Vigil Neuroscience Inc Asset Resilience Ratio
Vigil Neuroscience Inc asset resilience ratio. Vigil Neuroscience Inc (VIGL) has an Asset Resilience Ratio of 29.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vigil Neuroscience Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vigil Neuroscience Inc (2022–2024)
Asset resilience ratio of Vigil Neuroscience Inc from 2022 to 2024. This chart shows how Vigil Neuroscience Inc's Asset Resilience Ratio has changed over time. Read VIGL current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vigil Neuroscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VIGL total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $25.77 Million | 29.72% |
| Total Liquid Assets | $25.77 Million | 29.72% |
Asset Resilience Insights
- Very High Liquidity: Vigil Neuroscience Inc maintains exceptional liquid asset reserves at 29.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vigil Neuroscience Inc Industry Peers by Asset Resilience Ratio
Compare Vigil Neuroscience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Vigil Neuroscience Inc Asset Resilience Ratio by Year (2022–2024)
Vigil Neuroscience Inc asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Vigil Neuroscience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.94% | $58.78 Million | $117.69 Million | +3.12pp |
| 2023-12-31 | 46.82% | $65.95 Million | $140.86 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $200.39 Million | -- |
About Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more